SURMOUNT trial programme: difference between revisions
Diff·revision 22 → 23·15:45, 27 Sep 2025
Difference between revision 22 and revision 23 of SURMOUNT trial programme. 2 lines changed; the page grew by 300 bytes.
| Revision 22 — 14:16, 25 Aug 2025 NNT_Nerys (talk) the article attributed a finding to the wrong trial in the programme 4,721 bytes ±0 | Revision 23 — 15:45, 27 Sep 2025 Peptide_Pete (talk) de-orphan 5,021 bytes +300 | ||
|---|---|---|---|
| 39 | Nor does it establish comparative efficacy against [[Semaglutide|semaglutide]] 2.4 mg, which has never been studied head-to-head in obesity within this programme. Comparisons drawn between SURMOUNT-1 and [[STEP trial programme|STEP 1]] are cross-trial and are confounded by population, duration and escalation differences.{{r|ich_e9,wilding2021}} | 39 | Nor does it establish comparative efficacy against [[Semaglutide|semaglutide]] 2.4 mg, which has never been studied head-to-head in obesity within this programme. Comparisons drawn between SURMOUNT-1 and [[STEP trial programme|STEP 1]] are cross-trial and are confounded by population, duration and escalation differences.{{r|ich_e9,wilding2021}} |
| 40 | 40 | ||
| + | 41 | Means again conceal distribution: a substantial proportion of participants in every arm lost far more or far less than the mean, and the proportion achieving any given threshold is a more informative summary than the mean for a reader trying to understand the range of outcomes.{{r|jastreboff2022}} | |
| + | 42 | ||
| 41 | == References == | 43 | == References == |
| 42 | {{reflist}} | 44 | {{reflist}} |